NASDAQ:BTTX Better Therapeutics (BTTX) Stock Price, News & Analysis $0.01 +0.00 (+44.00%) (As of 09:33 AM ET) Add Compare Share Share Today's Range$0.0144▼$0.014450-Day Range$0.0061▼$0.014952-Week Range$0.01▼$1.35Volume5,000 shsAverage Volume3.41 million shsMarket Capitalization$717,984.00P/E RatioN/ADividend YieldN/APrice Target$6.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Better Therapeutics alerts: Email Address Ad Oasis GoldNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.Click Here To Get Your FREE Guide Now! About Better Therapeutics Stock (NASDAQ:BTTX)Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.Read More BTTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTTX Stock News HeadlinesMay 29, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Teleflex (TFX), Bioxcel Therapeutics (BTAI) and Prothena (PRTA)May 22, 2024 | businesswire.comClick Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc.July 8, 2024 | Oasis Gold (Ad)New Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.May 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Black Diamond Therapeutics Amid Strong Financials and Promising Clinical TrialsMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Leap Therapeutics on Strong Trial Prospects and Solid FinancialsMay 16, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Fortress Biotech (FBIO), GoodRx Holdings (GDRX) and Adaptimmune Therapeutics (ADAP)May 6, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Springworks Therapeutics (SWTX) and Becton Dickinson (BDX)May 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for Context Therapeutics Amid Promising CTIM-76 Developments and Competitive EdgeJuly 8, 2024 | Oasis Gold (Ad)New Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of opportunity to protect your interests is closing fast.April 26, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Bristol-Myers Squibb (BMY)April 10, 2024 | msn.comPrecision Combination Therapy Better Controls High-Risk Subtypes of B-ALL in Mouse ModelsMarch 16, 2024 | uk.investing.comBetter Therapeutics plans employee layoffs, strategic reviewMarch 14, 2024 | markets.businessinsider.comDow Dips Over 100 Points; Dick's Sporting Goods Earnings Top ViewsMarch 14, 2024 | businesswire.comBetter Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from NasdaqMarch 5, 2024 | businesswire.comBetter Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health CentersMarch 4, 2024 | finance.yahoo.comBetter Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)February 22, 2024 | finance.yahoo.comCAH Feb 2024 107.000 putFebruary 20, 2024 | benzinga.comWhy Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionSee More Headlines Receive BTTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Better Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Health services Sub-IndustryN/A Current SymbolNASDAQ:BTTX CUSIPN/A CIK1832415 Webmcacquisition.com Phone415-887-2311FaxN/AEmployees54Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$9.00 Low Stock Price Target$3.00 Potential Upside/Downside+41,566.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.04) per share Price / Book-0.36Miscellaneous Outstanding Shares49,862,000Free Float24,233,000Market Cap$718,012.80 OptionableOptionable Beta2.05 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesMr. David P. Perry M.B.A. (Age 56)Co-Founder & Executive Chairman Comp: $260kMr. Frank L. Karbe (Age 56)CEO, Interim CFO, President & Director Comp: $533.37kDr. Mark A. Berman M.D. (Age 48)Chief Medical Officer Comp: $573.75kMs. Kristin Wynholds (Age 51)Chief Product Officer Comp: $519.07kMr. Andres CamachoSenior VP of Technology & Head of EngineeringMs. Angela WillisSenior Vice President of Market AccessMs. Jessica MengChief Commercial OfficerLeslie MillerControllerMore ExecutivesKey CompetitorsBurgerFi InternationalNASDAQ:BFISafeguard ScientificsNYSE:SFEPrivia Health GroupNASDAQ:PRVALifeStance Health GroupNASDAQ:LFSTU.S. Physical TherapyNYSE:USPHView All CompetitorsInsidersDavid P PerryBought 1,233,045 shares on 7/27/2023Total: $900,122.85 ($0.73/share)Andrew J ArmaninoBought 274,010 shares on 7/27/2023Total: $200,027.30 ($0.73/share)Frank KarbeBought 137,005 shares on 7/27/2023Total: $100,013.65 ($0.73/share)Mark A BermanBought 54,802 shares on 7/27/2023Total: $40,005.46 ($0.73/share)View All Insider Transactions BTTX Stock Analysis - Frequently Asked Questions How have BTTX shares performed this year? Better Therapeutics' stock was trading at $0.1950 at the start of the year. Since then, BTTX stock has decreased by 92.6% and is now trading at $0.0144. View the best growth stocks for 2024 here. How do I buy shares of Better Therapeutics? Shares of BTTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BTTX) was last updated on 7/8/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored50-year Wall Street Legend: “Prepare for a cash avalanche”The Dow crossed 40,000 for the first time in history… The S&P has hit over 30 all-time highs since the star...Chaikin Analytics | SponsoredObama wins Presidential debate When I said Obama would seek a third term… They called me a conspiracy theorist, they said it couldn’t happ...Porter & Company | SponsoredTrump’s Gift Could Unleash $51 Billion in New WealthIn January 2021, Donald Trump silently rolled out a special gift to the American public… One that top house...Wealthpin Pro | SponsoredNew Government Policy to Wipe Out Seniors WealthDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredNvidia’s Quiet $1 Trillion PivotNvidia recently added $277 billion in market cap … IN ONE DAY.Weiss Ratings | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Better Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Better Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.